Joseph Dukes
Chief Scientific Officer Enara Bio
Joe joined Enara Bio in 2019 following leadership across research and early development of novel immunotherapies, having led molecules from early discovery and validation through to first-in-human clinical studies. Prior to joining Enara Bio, Joe spent eight years at Immunocore, developing novel TCR-based bispecific therapeutics. During this time, he established a bespoke, in vitro preclinical approach for generating safety data to de-risk TCR-based therapeutics. Joe obtained a PhD in Cell Biology and a subsequent post-doctoral fellowship at The University of Bath.
Seminars
Uncover how the field is moving beyond familiar targets like MAGE-A4 and PRAME to identify novel antigens that expand patient reach and improve clinical outcomes. This workshop dives into cutting-edge technologies, non-canonical targets, and next-generation engineering strategies that are redefining TCR therapy. Gain practical insights into building robust discovery pipelines, validating tumor specificity, and designing therapies that stand out in a competitive landscape.
Join this workshop to:
- Explore emerging target spaces including non-canonical antigens, alternative HLA molecules, and strategies to increase prevalence and density for broader patient access
- Find new ways to expedite the target validation process using a broad range of tools
- Apply computational tools to discover and validate targets faster and more accurately
- Design next-generation TCR formats to maximize efficacy and durability of response
